Fig. 5: Hypoxic signaling is preferentially required for brain versus breast tumor growth.
From: HIF1A signaling selectively supports proliferation of breast cancer in the brain
a Schema illustrating mixing experiments using shCtrl and shHIF1A CTCs to establish brain and mammary tumors. b GSEA of transcripts differentially expressed in Brx-142 shCtrl versus shHIF1A_A8 cells (fold change >2; FDR < 0.25). The most enriched Hallmarks of Cancer gene sets from the Broad Molecular Signatures Database and associated FDR values are shown. Hypoxia and glycolysis genesets are highlighted. c shHIF1A tumor fraction as compared to input fraction in brain or breast tumors from Brx-82 or Brx-142 mixing experiments. shHIF1A tumor fraction was determined via next-generation sequencing for the hairpin sequences corresponding to shCtrl, shHIF1A_A8, and shHIF1A_A9 (shHIF1A_A8 brain: n = 2; shHIF1A_A9 brain: n = 3; all mammary: n = 4). Dotted line indicates unchanged shHIF1A and shCtrl fractions from input. d Brain or mammary tumor luminescence monitored following stereotactic injection of Brx-82 cells (brain 0 g/L DCA: n = 8; brain 0.1 g/L DCA: n = 4; all mammary: n = 4). Mice were treated for 8 weeks with 0.1 g/L DCA or vehicle delivered in drinking water. P values calculated by the extra sum-of-squares F test. Data for in vitro experiments represent mean ± SD and for in vivo experiments represent mean ± SEM. Source data are provided as a Source Data file.
